Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.53 |
| ▸ | CTSS | P25774 | 10/20 | 0.53 |
| ▸ | CTSK | P43235 | 8/20 | 0.53 |
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588912 | 1.00 | PPARA (0.53) | PPARACTSSCTSKPPARGCTSL | |
| SCHEMBL527131 | 1.00 | PPARA (0.53) | PPARACTSSCTSKPPARGCTSL | |
| SCHEMBL8130419 | 0.95 | PPARA (0.50) | PPARACTSSCTSKPPARGCTSL | |
| SCHEMBL30448077 | 0.88 | PPARA (0.50) | PPARACTSSCTSKPPARGCTSL | |
| SCHEMBL1278066 | 0.88 | PPARA (0.53) | PPARACTSSCTSKPPARGCTSL | |
| SCHEMBL27398769 | 0.87 | PPARA (0.55) | PPARACTSSCTSKPPARGCTSL | |
| SCHEMBL27398770 | 0.87 | PPARA (0.55) | PPARACTSSCTSKPPARGCTSL | |
| SCHEMBL25262348 | 0.86 | CTSK (0.48) | PPARACTSSCTSKPPARGCTSL | |
| SCHEMBL953455 | 0.86 | CTSK (0.48) | PPARACTSSCTSKPPARGCTSL | |
| SCHEMBL953453 | 0.86 | CTSK (0.48) | PPARACTSSCTSKPPARGCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4678238-A2 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| US-12486262-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4651947-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651946-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651945-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651948-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651953-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-1998035982-A1 | COMPOUNDS FOR USE IN ADEPT | ZENECA LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
| WO-1997027304-A9 | PARA-NITROBENZYL ESTERASES WITH ENHANCED ACTIVITY IN AQUEOUS AND NONAQUEOUS MEDIA | — | 1997-10-09 | — | — | WO | disclosed |
| WO-1997027304-A1 | PARA-NITROBENZYL ESTERASES WITH ENHANCED ACTIVITY IN AQUEOUS AND NONAQUEOUS MEDIA | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0122018-B1 | IMPROVEMENTS IN AND RELATING TO PHARMACOLOGICALLY ACTIVE TRIPEPTIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1987-09-02 | — | — | EP | disclosed |
| US-4517379-A | ARTIFICIAL SWEETENER | PFIZER INC. (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0069811-B1 | BRANCHED AMIDES OF L-ASPARTYL-D-AMINO ACID DIPEPTIDES AND COMPOSITIONS THEREOF | PFIZER INC. (US) | 1984-10-24 | — | — | EP | disclosed |
| EP-0122018-A2 | Improvements in and relating to pharmacologically active tripeptide derivatives | ELI LILLY AND COMPANY (US) | 1984-10-17 | — | — | EP | disclosed |
| US-4454328-A | SWEETENERS | PFIZER INC. (US) | 1984-06-12 | — | — | US | disclosed |
| US-4399163-A | ARTIFICIAL SWEETENERS | PFIZER INC. (US) | 1983-08-16 | — | — | US | disclosed |
| EP-0069811-A1 | Branched amides of L-aspartyl-D-amino acid dipeptides and compositions thereof | PFIZER INC. (US) | 1983-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | PPARA 2794/4885CTSS 4022/4885CTSK 4661/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | PPARA 3869/4885CTSS 1281/4885CTSK 2087/4885 |
| US-12486262-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | PPARA 1483/4885CTSS 2010/4885CTSK 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.